Clinical Trials Browser

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasm, Residual

Multiple Myeloma

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Smoldering Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms

Multiple Myeloma, Plasmacytoma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Clinical Trials

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

CARTITUDE-2

CARTITUDE-6

IFm2022-01

A Study of Daratumumab

EMAT

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

AURIGA

MajesTEC-2

CARTITUDE-5

MonumenTAL-2

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

aMMbition

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

MajesTEC-7

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

PLYCOM

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

KarMMa-9

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

KarMMa-2

(COBRA)

MagnetisMM-6

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

HEME-18

LINKER-MM8

QUAD

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

MajesTEC-4

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Perseus

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

KRDI in Transplant-Eligible MM

iinnovate-2

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant